These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32065620)

  • 1. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.
    Corcoran D; Radjenovic A; Mordi IR; Nazir SA; Wilson SJ; Hinder M; Yates DP; Machineni S; Alcantara J; Prescott MF; Gugliotta B; Pang Y; Tzemos N; Semple SI; Newby DE; McCann GP; Squire I; Berry C
    Cardiovasc Res; 2021 Jan; 117(1):320-329. PubMed ID: 32065620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
    Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M
    Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP).
    Gifford FJ; Dunne PDJ; Weir G; Ireland H; Graham C; Tuck S; Hayes PC; Fallowfield JA
    Trials; 2020 Mar; 21(1):260. PubMed ID: 32164767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
    Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M
    Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of heart rate reduction with ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease.
    Hohneck AL; Fries P; Ströder J; Schneider G; Wagenpfeil S; Schirmer SH; Böhm M; Laufs U; Custodis F
    J Hypertens; 2019 May; 37(5):1023-1031. PubMed ID: 30672832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Serelaxin in Patients with Acute Heart Failure.
    Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C;
    N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
    Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
    Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
    Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
    J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.
    Snowdon VK; Lachlan NJ; Hoy AM; Hadoke PW; Semple SI; Patel D; Mungall W; Kendall TJ; Thomson A; Lennen RJ; Jansen MA; Moran CM; Pellicoro A; Ramachandran P; Shaw I; Aucott RL; Severin T; Saini R; Pak J; Yates D; Dongre N; Duffield JS; Webb DJ; Iredale JP; Hayes PC; Fallowfield JA
    PLoS Med; 2017 Feb; 14(2):e1002248. PubMed ID: 28245243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
    Teerlink JR; Davison BA; Cotter G; Maggioni AP; Sato N; Chioncel O; Ertl G; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Edwards C; Senger S; Teichman SL; Nielsen OW; Voors AA; Metra M
    Eur J Heart Fail; 2020 Feb; 22(2):315-329. PubMed ID: 31886953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of N-terminal Pro-brain Natriuretic Peptide and Myocardial Perfusion in Asymptomatic Adults (from the Multi-Ethnic Study of Atherosclerosis).
    Mitchell A; Misialek JR; Folsom AR; Duprez D; Alonso A; Jerosch-Herold M; Sanchez OA; Watson KE; Sallam T; Konety SH
    Am J Cardiol; 2015 May; 115(10):1341-5. PubMed ID: 25816778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial.
    Pang PS; Teerlink JR; Voors AA; Ponikowski P; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Kriger J; Prescott MF; Hua TA; Severin T; Metra M
    JACC Heart Fail; 2016 Jul; 4(7):591-599. PubMed ID: 27039129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.
    Weiss G; Teichman S; Stewart D; Nader D; Wood S; Breining P; Unemori E
    BMC Pregnancy Childbirth; 2016 Sep; 16(1):260. PubMed ID: 27596360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
    Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
    Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
    Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M
    Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
    Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
    Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.
    Wolf VL; Phillips TL; Taylor EB; Sasser JM; Ryan MJ
    Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H234-H242. PubMed ID: 31125285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
    Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
    J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation.
    Leo CH; Jelinic M; Parkington HC; Tare M; Parry LJ
    J Am Heart Assoc; 2014 Feb; 3(1):e000493. PubMed ID: 24584737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial.
    Filippatos G; Teerlink JR; Farmakis D; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua T; Ponikowski P; Severin T; Unemori E; Voors AA; Metra M
    Eur Heart J; 2014 Apr; 35(16):1041-50. PubMed ID: 24316514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.